Table 2.
Comorbidities and pathologic serologic parameters in 259 patients with PG
| Patients (absolute) | Patients (relative in%) | |
|---|---|---|
|
Gastrointestinal diseases |
66 |
22.5 (overall) |
| Chronic active hepatitis |
11 |
16.7 |
| Ulcerative colitis |
17 |
25.8 |
| Crohn’s disease |
7 |
10.6 |
| Diverticulosis |
9 |
13.6 |
| Gastric disorders |
13 |
19.7 |
| Gastric/duodenal ulcer |
4 |
6.0 |
| Gastrointestinal polyps |
2 |
3.0 |
| Steatohepatitis |
1 |
1.5 |
| Others |
2 |
3.0 |
|
Arthropathy |
48 |
18.5 (overall) |
| Rheumatoid arthritis |
24 |
50.0 |
| a) seropositive |
21 |
43.8 |
| b) seronegative |
3 |
6.3 |
| Arthrosis |
17 |
25.8 |
| Ankylosing spondylitis |
2 |
4.1 |
| Psoriasis arthropathy |
3 |
6.3 |
| Osteoporosis |
2 |
4.1 |
|
Haematological diseases |
10 |
3.9 (overall) |
| Leukemia |
3 |
30.0 |
| a) AML |
1 |
10.0 |
| b) CML |
2 |
20.0 |
| Lymphoma (T-cell) |
2 |
20.0 |
| Multiple myeloma |
2 |
20.0 |
| Macroglobulinemia |
3 |
30.0 |
|
Neoplasia |
22 |
8.5 (overall) |
| Breast cancer |
6 |
27.3 |
| Lung cancer |
3 |
13.6 |
| Prostate cancer |
3 |
13.6 |
| Malignant melanoma |
3 |
13.6 |
| Hepatocellular carcinoma |
2 |
9.1 |
| Ovarian cancer |
2 |
9.1 |
| Colorectal cancer |
1 |
4.5 |
| Laryngeal cancer |
1 |
4.5 |
| Glioblastoma |
1 |
4.5 |
|
Endocrine disorders |
95 |
36.7 (overall) |
| Diabetes mellitus |
66 |
69.5 |
| a) type II |
60 |
63.2 |
| b) type I |
6 |
6.3 |
| Thyroid disease |
29 |
30.5 |
| Hyperthyroidism |
9 |
9.5 |
| Hypothyroidism |
18 |
19.0 |
| Hashimoto’s thyroiditis |
2 |
2.1 |
|
Serological parameters |
181 |
69.9 (overall) |
| Anemia |
118 |
65.2 |
| Microcytic anaemia |
28 |
15.5 |
| Auto-antibodies |
45 |
24.9 |
| Anti-nuclear antibodies |
30 |
16.6 |
| C-reactive protein |
181 |
100 |
| Leukocytosis |
117 |
64.6 |
| Elevated creatinine |
52 |
28.7 |
| Renal failure | 11 | 6.1 |